Polyethylene Glycol (PEG) Versus Lactulose in the treatment of Hepatic Encephalopathy
Phase 3
Completed
- Conditions
- Health Condition 1: null- All patients diagnosed with Hepatic Encephalopathy presenting to the inpatient care at the department of Gastroenterology, IMS, BHU.Health Condition 2: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2017/07/008995
- Lead Sponsor
- Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 57
Inclusion Criteria
1. All patients diagnosed with Hepatic Encephalopathy presenting to the inpatient care at the department of Gastroenterology, IMS, BHU
2. Age 18 to 80 years
3. Diagnosis of Chronic Liver Disease from any cause
4. The availability of a Legally Authorized Representative for interview and consent
Exclusion Criteria
1.Patients with Hepatic Encephalopathy
Grade I and Grade IV.
2.Acute Liver failure
3.More than 1 dose of lactulose before
consent
4.No Legally Authorized Representative to
give consent/ Refusal of consent
5.Previously recruited in the present
study
6.Serum Creatinine more than 2.5 mg /dl
7.Treated with Vasopressors
8.Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in HESA ScoreTimepoint: 24 Hours
- Secondary Outcome Measures
Name Time Method Deterioration in HESA Score, Refusal, Discharge or DeathTimepoint: 24 hours and Within a week after recruitment